Clinical Evaluation of PoreSkin

Clinical Evaluation of PoreSkin: A Human Acellular Dermal Matrix

PoreSkin, a human acellular dermal matrix (hADM) manufactured by Faculty of Medicine, Chulalongkorn University, is the first human dermal substitute developed in Thailand. It is a permanent dermal substitute aiming to reduce skin contracture. The objective of this study is to assess the safety and ability in achieving durable and cosmetic coverage of PoreSkin.

Inclusion Criteria:

• Male and female patients
• 18-60 years with burn scar contracture and hypertrophic scar

Exclusion Criteria:

• Undergoing immunosuppressive therapy
• Immunocompromise host (DM, HIV infected)
• Evidence of malnutrition
• Active malignancy